Scientifically Adept - Platform Agnostic: Particle Sciences Positions Itself as a Bioavailability Tool for Most Dosage FormsJanuary 22, 2015 | by Mike Auerbach, Editor In Chief | Comments
Particle Sciences, a drug development services company located in Bethlehem, Pennsylvania, has based its business model on being platform/technology agnostic. Bring them your drug development, formulation or dosage form problem and they will apply the right set of tools and technology to advance your project.
With new mAb drugs such as Kadcyla costing over 100,000 Euros per year, the price per patient...
Clean rooms are the standard for cGMP-compliant manufacturing, but the significant time and high costs of manufacturing and maintenance, as well as the lack of mobility, makes them difficult to justify.
As global demand for bottle-packaged pharmaceuticals grows, incremental upgrades in desiccant canister design yield substantial performance improvements.
Like so many industries, pharmaceutical processing is increasingly focused on improving the operational energy efficiency. One challenge that often stands in the way: cleanrooms. In these facilities, energy efficiency understandably takes a back seat to the mission of clean production. As a result, due to FDA-required filtration, high-performance processing machines and other factors, cleanrooms are energy intensive.
Dust has always been an unwanted byproduct of tablet manufacturing. In a perfect world, all powder would flawlessly flow into the hopper, and 100% of the product would emerge as finished tablets. In practice, though, most tablet presses are so inundated with dust after an eight-hour run that they form miniature snow piles on both sides of the feeder, and build-ups of material occur around the takeoff bar and recirculation channel.
Biosimilars have increasingly become an important and somewhat controversial topic in the healthcare space. Depending on who one speaks to, the opinion on biosimilars changes. However, there are certain truths that all stakeholders should keep in mind.
SAFC, a global supplier of a a wide range of services to the biopharm and pharmaceutical industry, has recently expanded their Madison, Wisconsin facilities to neighboring Verona to rev up their high-potency API manufacturing capabilities.
When it comes to the supply chain, business can be risky. A seminal survey of companies in various industries spanning 62 countries found 85% of respondents have experienced a supply chain disruption over the last 12 months, and 50% of companies had more than one disruption.
The development of new chemistry-based products for life science markets requires the expertise of talented researchers. However, these same researchers are typically not prepared to solve the many other critical problems necessary for successful commercialization.
Capsugel acquires Bend Research and Encap Drug Delivery to create a comprehensive solid dosage form solutions group.
SAFC, a global company that supplies a multitude of services to the biopharm/pharmaceutical industry has recently opened a new Dry Powder Media (DPM ) manufacturing facility in Irvine, Scotland to complement their Lenexa, KS DPM facility. By doing so SAFC has shown their commitment to their customers and this growing segment of the pharmaceutical industry.
Due to the special containment requirements for manufacturing highly potent active pharmaceutical ingredients and cytotoxic drugs, we have seen many CMO’s invest in building additional capacity in this area. While there are tremendous benefits and a strong promise with these types of products there are also considerable challenges and risks associated with their production, especially in a multiproduct CMO environment.
When it comes to the inspection of cleaned equipment of pharmaceutical manufacturing equipment, there are currently no industry-mandated standards. Instead, various companies have had their own internal procedures for inspecting cleaned equipment, with visual inspection widely used as the primary method.
As serialization becomes an ever more important part of the pharmaceutical industry and the FDA's track & trace deadlines loom in the distance, we sat down with Kelly Ng, the Healthcare division's Product Manage at Epson, to talk about the state of track and trace/serialization technology, whether the industry is ready for the new requirements and how companies can make sure that they will make the upcoming deadlines.
Mention the terms ‘cell therapy’ or ‘regenerative medicine’ and many in the general public are still confused as to what those terms actually mean. But those in the know understand that cell therapy is a growing and thriving industry, with great potential to change the face of modern healthcare.
During the last quarter of 2013, PwC surveyed more than 1,300 business leaders across 68 countries around the world, and the pharmaceutical and life sciences sector was well represented. The results showed a number of positives for all businesses, notably a leap in CEOs’ confidence in the global economy. But PLS leaders are cautious as to whether this will translate into better prospects for their own companies.